SK1742001A3 - Crystalline forms of osanetant - Google Patents

Crystalline forms of osanetant Download PDF

Info

Publication number
SK1742001A3
SK1742001A3 SK174-2001A SK1742001A SK1742001A3 SK 1742001 A3 SK1742001 A3 SK 1742001A3 SK 1742001 A SK1742001 A SK 1742001A SK 1742001 A3 SK1742001 A3 SK 1742001A3
Authority
SK
Slovakia
Prior art keywords
osanetant
mixture
crystalline form
cooled
ethanol
Prior art date
Application number
SK174-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Alain Alcade
Gilles Anne-Archard
Patrick Grosclaude
Olivier Monnier
Jerome Roche
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of SK1742001A3 publication Critical patent/SK1742001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK174-2001A 1998-08-05 1999-08-03 Crystalline forms of osanetant SK1742001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810107A FR2782082B3 (fr) 1998-08-05 1998-08-05 Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
PCT/FR1999/001914 WO2000007987A1 (fr) 1998-08-05 1999-08-03 Formes cristallines du osanetant

Publications (1)

Publication Number Publication Date
SK1742001A3 true SK1742001A3 (en) 2001-11-06

Family

ID=9529458

Family Applications (1)

Application Number Title Priority Date Filing Date
SK174-2001A SK1742001A3 (en) 1998-08-05 1999-08-03 Crystalline forms of osanetant

Country Status (32)

Country Link
US (1) US7041679B2 (es)
EP (1) EP1102747B1 (es)
JP (1) JP3807938B2 (es)
KR (1) KR100571944B1 (es)
CN (1) CN1114592C (es)
AR (1) AR019953A1 (es)
AT (1) ATE243197T1 (es)
AU (1) AU748177B2 (es)
BR (1) BR9913357A (es)
CA (1) CA2339007A1 (es)
CO (1) CO5070576A1 (es)
DE (1) DE69908951T2 (es)
DK (1) DK1102747T3 (es)
DZ (1) DZ3074A1 (es)
EA (1) EA003205B1 (es)
EE (1) EE04274B1 (es)
ES (1) ES2200535T3 (es)
FR (1) FR2782082B3 (es)
HK (1) HK1035535A1 (es)
HU (1) HUP0103134A3 (es)
IS (1) IS5821A (es)
MY (1) MY121447A (es)
NO (1) NO320645B1 (es)
NZ (1) NZ509561A (es)
PL (1) PL345999A1 (es)
PT (1) PT1102747E (es)
SK (1) SK1742001A3 (es)
TR (1) TR200100261T2 (es)
TW (1) TW527354B (es)
UA (1) UA72890C2 (es)
WO (1) WO2000007987A1 (es)
YU (1) YU8601A (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
WO2023278843A2 (en) * 2021-07-02 2023-01-05 Acer Therapeutics, Inc. Solid forms of osanetant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
WO1998005640A2 (en) * 1996-08-05 1998-02-12 Smithkline Beecham S.P.A. Process for the preparation of 3,3-disubstituted piperidines
US6040316A (en) * 1996-09-16 2000-03-21 Warner-Lambert Company 3-alkyl-3-phenyl-piperidines
FR2757543B1 (fr) * 1996-12-23 1999-04-02 Sanofi Sa Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues

Also Published As

Publication number Publication date
EE200100070A (et) 2002-06-17
AU748177B2 (en) 2002-05-30
AU5168599A (en) 2000-02-28
US7041679B2 (en) 2006-05-09
DZ3074A1 (fr) 2004-07-20
WO2000007987A1 (fr) 2000-02-17
EP1102747A1 (fr) 2001-05-30
CN1314888A (zh) 2001-09-26
NO20010553D0 (no) 2001-02-01
EE04274B1 (et) 2004-04-15
NO20010553L (no) 2001-04-05
EA200100096A1 (ru) 2001-08-27
JP3807938B2 (ja) 2006-08-09
EP1102747B1 (fr) 2003-06-18
TR200100261T2 (tr) 2001-06-21
JP2002522419A (ja) 2002-07-23
EA003205B1 (ru) 2003-02-27
DK1102747T3 (da) 2003-09-29
CA2339007A1 (en) 2000-02-17
BR9913357A (pt) 2001-05-15
DE69908951D1 (de) 2003-07-24
AR019953A1 (es) 2002-03-27
PT1102747E (pt) 2003-09-30
KR100571944B1 (ko) 2006-04-18
FR2782082B3 (fr) 2000-09-22
ES2200535T3 (es) 2004-03-01
ATE243197T1 (de) 2003-07-15
KR20010072220A (ko) 2001-07-31
US20040044215A1 (en) 2004-03-04
FR2782082A1 (fr) 2000-02-11
HUP0103134A3 (en) 2003-03-28
NO320645B1 (no) 2006-01-09
MY121447A (en) 2006-01-28
IS5821A (is) 2001-01-23
TW527354B (en) 2003-04-11
HK1035535A1 (en) 2001-11-30
DE69908951T2 (de) 2004-05-19
CN1114592C (zh) 2003-07-16
CO5070576A1 (es) 2001-08-28
PL345999A1 (en) 2002-01-14
UA72890C2 (en) 2005-05-16
NZ509561A (en) 2002-10-25
YU8601A (sh) 2003-07-07
HUP0103134A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
TW201024292A (en) Crystalline forms of a potent HCV inhibitor
NO171453B (no) Fremgangsmaate for fremstilling av krystallinsk paroxetin-hydroklorid-hemihydrat
SK20262000A3 (sk) Metánsulfonát paroxetínu v kryštalickej forme, spôsob jeho výroby, farmaceutický prostriedok s jeho obsahom a jeho použitie
US20080194827A1 (en) Crystalline forms of Donepezil base
WO1992017473A1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
SK1742001A3 (en) Crystalline forms of osanetant
US6939856B2 (en) Method for preparing dexchlor tannate
JP2002532470A (ja) パロキセチンマレイン酸塩の製法
CA2164296C (en) Heterocyclic chemistry
RU2192416C2 (ru) Способ кристаллизации гидрохлорида 1-[2-(2-нафтил)этил]-4-(3-трифторметилфенил)-1,2,3,6-тетрагидропиридина, полученные кристаллические формы и фармацевтическая композиция
JPH06192228A (ja) 結晶性（ｒ）−（−）−２−シクロヘプチル−ｎ−メチルスルフオニル−［４−（２−キノリニルメトキシ）−フエニル］−アセトアミド
US20050107396A1 (en) Stable crystalline form of bifeprunox mesylate (7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
JP2007502802A (ja) ビフェプルノックスメシラートの安定な多形体
CZ2001420A3 (cs) Krystalické formy osanetantu
WO2005023769A1 (en) Process for the preparation of amlodipine salts
EP2072510A1 (en) Crystalline form of azelastine
EP1135383B1 (en) Mixed paroxetine propan-2-ol solvates
MXPA01001282A (es) Formas cristalinas del osanetant
JPH08231543A (ja) Ｎ−［４−［２−（２，４−ジメチルフエノキシ）フエニル］−２−チアゾリル］−１，４，５，６−テトラヒドロ−２−ピリミジンアミン（ｄｔｔｐ）の熱力学的安定形態物
JP4693236B2 (ja) １−メチル−５−ｐ−トルオイルピロール−２−アセトアミド酢酸グアイアシルエステル（ＭＥＤ１５）の新規多形結晶
EA004298B1 (ru) Гидроиодид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона в качестве фармацевтического препарата
CZ20003678A3 (cs) Krystalické formy 1S-[1alfa(2S*,3R*), 9 alfa]-6,10-dioxo-N-(2-etoxy-5-oxo-tetrahydro-3-furyl)-9-[[(1-isochinolyl)karbonyl]amino]oktahydro-6H-pyridazino[1,2-A][1,2]diazepin-1-karboxamidu
WO2000078752A1 (en) Process for the production of paroxetine hydrochloride
CZ20002325A3 (cs) Termodynamicky stabilní modifikace I ramatrobanu, způsob její výroby a její použití
WO2001012624A1 (en) Paroxetine